In this study, we directly compared the anti-obesity efficacy of LJ-4378, a dual A2A agonist/A3 antagonist, with that of TZP, a dual GLP-1/GIP receptor agonist with proven clinical efficacy. Here, GLP1R is linked to obesity disorder.